New 'Reference Regimen' in Metastatic Pancreatic Cancer?

Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/987317?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension